Helicase mutant and use thereof
By modifying amino acids in the flexible region of helicase, it improves its thermal stability and sequencing performance, the problem of poor thermal stability of helicase in nanopore sequencing is solved, and higher sequencing accuracy and throughput are achieved.
Patent Information
- Application Number
- PCT/CN2024/096255
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-02
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
In the existing nanopore sequencing technology, the helicase has poor thermal stability in a long-term heating environment, resulting in uneven sequencing speed, reduced accuracy and reduced flux, especially in high-temperature environments in the wild.
By performing amino acid modification in the flexible region of the helicase, its thermal stability and sequencing performance are improved, for example, by modifying the Loop region and amino acid residues with higher B factor, the Tm value of the helicase and the maintenance of activity.
Improve understanding of the thermal stability and sequencing performance of helicase, reduce sequencing speed, increase sequencing readouts and throughput, extend the sequencing time, and improve the accuracy and data volume of sequencing results.
Smart Images

Figure PCTCN2024096255-FTAPPB-I100001 
Figure PCTCN2024096255-FTAPPB-I100002 
Figure PCTCN2024096255-FTAPPB-I100003
Abstract
Description
Helicase mutants and their applications Technical Field
[0001] The present invention belongs to the technical field of detecting and characterizing target analytes, and specifically relates to a helicase mutant and applications thereof, in particular for nanopore sequencing. Background Art
[0002] Nucleic acid sequencing technology has continued to develop with the advancement of research into nucleic acid structure and sequence, becoming a core area of life science research and significantly driving technological advancements in biology, chemistry, electronics, life sciences, medicine, and other fields. The development of novel, rapid, accurate, low-cost, high-precision, and high-throughput nucleic acid sequencing technologies using nanopores is a key focus of the post-Human Genome Project.
[0003] Nanopore sequencing technology, also known as the fourth-generation sequencing technology, is a sequencing technology that uses target analytes such as single-stranded nucleic acid molecules as sequencing units. It uses a nanopore that can provide an ion current channel to allow target analytes such as single-stranded nucleic acid molecules to pass through the nanopore under the drive of electric potential. When the target analyte passes through the nanopore, the current of the nanopore will be reduced, and the sequence information of the different signals generated will be read in real time.
[0004] The key features of nanopore sequencing are its extremely long read lengths and high accuracy. Nanopore sequencing not only enables sequencing of native DNA and RNA but also directly captures base modification information in DNA and RNA. For example, it can directly read methylated cytosines without requiring prior bisulfite treatment of the genome, as required by second-generation sequencing methods. This significantly advances the direct study of epigenetic phenomena at the genomic level. As a novel platform, nanopore detection technology offers advantages such as low cost, high throughput, and label-free operation.
[0005] When a potential is applied to the nanopore (transmembrane pore), an analyte such as a polynucleotide passing through the nanopore will produce a change in the electrical signal. Nanopore detection of the analyte such as a polynucleotide can produce an electrical signal change of known signal and duration. In the chain sequencing method, an analyte such as a single polynucleotide chain passes through the nanopore and can achieve the identification of the nucleotide. The electrical signal changes caused by the passage of resolvable single-stranded DNA or RNA through the nanopore recorded within the existing sampling range are largely due to the control of rate-controlling enzymes such as helicases that control or slow down the speed of DNA / RNA molecules passing through the nanopore.
[0006] In current sequencing systems, rate-controlling enzymes such as helicases are in a continuously heated sequencing environment. Long-term heating may cause obstacles to the coupling of ATP binding hydrolysis and helicase displacement, resulting in uneven or jammed enzyme movement speed, or the helicase may separate from single-stranded DNA due to enzyme denaturation, resulting in reduced accuracy and throughput. On the other hand, a major advantage of the nanopore sequencing platform is its simplicity and portability, which allows real-time detection at any location according to user needs. In order to expand the application scenarios of the nanopore sequencing platform, such as high-temperature environments in the wild, helicases with higher thermal stability are needed.
[0007] Therefore, there is a need for a helicase with improved sequencing performance and / or higher thermostability.
[0008] Summary of the Invention
[0009] In order to solve the above technical problems, the present invention provides a helicase mutant and its application.
[0010] In a first aspect, the present invention provides a helicase mutant whose flexible region is rigidified and retains the ability to control the movement of a polynucleotide through a nanopore.
[0011] In one embodiment, the helicase mutant has improved sequencing performance, such as reduced sequencing speed, increased number of sequencing reads within the same sequencing time (or increased pore frequency), increased sequencing throughput and / or extended sequencing time, compared to the corresponding helicase without rigidification of the flexible region.
[0012] Reduced sequencing speed, increased sequencing throughput, increased number of sequencing reads within the same sequencing time (or increased frequency of perforations), and extended sequencing time are not necessarily required for every mutant to simultaneously improve sequencing performance. Preferred mutants may have one or more of the above-mentioned performance improvements. When sequencing speeds are similar, some mutants will obtain more reads within the same sequencing time, thereby improving sequencing throughput. Some mutants have reduced sequencing speeds, but the reduced speed may improve the accuracy of sequencing. The increase in the number of sequencing reads within the same sequencing time can compensate for the reduced throughput caused by the speed reduction, and even obtain a higher throughput. Generally speaking, mutants with higher thermal stability (i.e., relatively high Tm values) are easier to maintain under heated sequencing conditions, can work normally for a longer time, and are also conducive to obtaining a higher throughput. A proper reduction in sequencing speed is more conducive to electrical signal analysis, and an extension of sequencing time is conducive to increasing sequencing throughput and increasing the amount of data, all of which are conducive to improving the accuracy of the analysis results.
[0013] In one embodiment, the flexible region is rigidified by modifying one or more amino acids in the loop region and / or at amino acid residues with higher B factors. In one embodiment, the amino acid residues with higher B factors are selected from the top 50, 40, 30, 20 or 10 amino acids with the highest B factors in the helicase sequence. In one embodiment, the amino acid residues with higher B factors are selected from the top 20%, 10%, 5%, 2% or 1% of amino acid residues in the helicase sequence with the highest B factor values. In one embodiment, the B factor is predicted using B-Fitter software.
[0014] In one embodiment, the helicase mutant has improved thermal stability compared to the corresponding helicase without rigidification of the flexible region, and optionally the Tm value of the helicase mutant is increased by at least about 0.5°C, about 1°C, about 2°C, about 3°C, about 4°C, about 5°C, about 6°C, about 7°C, about 8°C, preferably at least about 10°C compared to the corresponding helicase without rigidification of the flexible region. The thermal stability can be measured under locked enzyme or naked enzyme conditions.
[0015] In a preferred embodiment, the helicase mutant retains helicase activity, ATPase activity and substrate binding ability on the basis of improved thermostability.
[0016] In one embodiment, the corresponding helicase without rigidification of the flexible region is a helicase of helicase superfamily 1 or superfamily 2 or a functional variant thereof, preferably a Pif1-like helicase, Upf1-like helicase, UvrD / Rep helicase, Ski-like helicase, Rad3 / XPD helicase, NS3 / NPH-II helicase, DEAD helicase, DEAH / RHA helicase, RecG The helicase may be a Pif1-like helicase, a REcQ-like helicase, a T1R-like helicase, a Swi / Snf-like helicase or a Rig-I-like helicase or a functional variant thereof, more preferably a Pif1-like helicase, further preferably a Hel308 helicase or a functional variant thereof, a RecD helicase or a functional variant thereof, a TraI helicase or a functional variant thereof, an XPD helicase or a functional variant thereof, or a Dda helicase or a functional variant thereof, such as a T4-Dda helicase or a functional variant thereof, such as the Pif1-like helicase disclosed in CN113930406A, for example, a Pectobacterium phage PM2 Pif1-like helicase (Uniprot ID: A0A0A0Q3A4), an Acinetobacter phage Acj61 Pif1-like helicase (Uniprot ID: E5E403), an Aeromonas phage PX29 Pif1-like helicase (Uniprot ID: E5DQH4), Cinqassovirus aeh1 Pif1-like helicase (Uniprot ID: Q76YI7), Serratia phage CBH8 Pif1-like helicase (Uniprot ID: A0A1Z1LY03), Edwardsiella phage PEi26 Pif1-like helicase (Uniprot ID: A0A0B6VP37), Acinetobacter phage AM101 Pif1-like helicase (Uniprot ID: A0A4Y1NMU3), Pseudomonas phage PspYZU05 Pif1-like helicase (Uniprot ID: A0A2U7NRX4), Escherichia phage EcS1 Pif1-like helicase (Uniprot ID: A0A1Z1LY03),
[0015] The helicases described herein include, but are not limited to, those from Erwinia phage Cronus Pif1-like helicase (Uniprot ID: A0A2S1GM41), and Morganella phage vB_MmoM_MP1 Pif1-like helicase (Uniprot ID: A0A192Y9K3). Corresponding helicases without rigidified flexible regions can also be selected from the helicases shown in SEQ ID NO: 1 to SEQ ID NO: 21.
[0017] In one embodiment, the corresponding helicase without rigidification of the flexible region comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity to the amino acid sequence of SEQ ID NO: 1, and the helicase mutant has one or more amino acid modifications at the following positions corresponding to SEQ ID NO: 1: G158, S159, G161, A432, and G435. The amino acid modifications include deletion or substitution with other amino acids having larger side chains or greater rigidity. For the G158 site, optional amino acid modifications include deletion or substitution with P / N / Q; for the S159 site, optional amino acid modifications include deletion or substitution with D / E / A / T / Y / N / Q; for the G161 site, optional amino acid modifications include deletion or substitution with E / Q / T / I / V / L / S / M / N / Y; for the A432 site, optional amino acid modifications include substitution with L / V / I / T / S / M / Y / N / Q / P / W / F; for the G435 site, optional amino acid modifications include substitution with A / S / L / V / I / T / M / Y / N / Q / P / W / F. Preferably, the helicase mutant has one or more of the following amino acid modifications: ΔG158 / ΔS159, ΔG161, A432L, G435A.
[0018] In one embodiment, the corresponding helicase without rigidification of the flexible region comprises an amino acid sequence as shown in any one of SEQ ID NOs: 1-21, or an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity to the amino acid sequence as shown in any one of SEQ ID NOs: 1. In one embodiment, the helicase mutant is selected from:
[0019] (a) A variant of the sequence shown in SEQ ID NO: 1, which has one or more amino acid modifications at the following positions: G158, S159, G161, A432, G435, V5-N11, R28-E31, P38-G42, G58-G61, A66-T68, G80-T85, K91, Y97-Q100, R106-N115, D120E121, L125D126, I137-C141, D148-S166, H171-S173, L179-A 187, G199-H204, D208G209, F215-A220, K233-E240, Y246T247, Y263-N271, Q278-P280, D288-G289, N298-N29 9. I316-K323, I336-I344, L350-L352, E371-P380, F391-K393, L397P398, Q406-N411, T417-D419, A423-E424;
[0020] (b) a variant of the sequence shown in SEQ ID NO: 2, which has one or more amino acid modifications at the following positions: G159, A160, E162, L428, G431, M1-T7, V24-R32, P39-G43, G59-G62, A67-T69, G81-T86, K92, Y98-S101, K107-R116, D121E122, Y126D127, I138-C142, D149-S166, H171-K173, L179- A187, G199-E204, D208G209, L215-S220, K233-E240, F246T247, Y263-D271, Q278-P280, E288G289, N298N29 9. S316-K323, L336-T342, I348-D350, S370-A376, F387-K389, L393P394, Q402-D407, T413-C415, A419D420;
[0021] (c) a variant of the sequence shown in SEQ ID NO: 3, which has one or more amino acid modifications at the following positions: G155, S156, Q158, A428, G431, I2-N8, R25-E28, , P35-G39, G55-G58, A63-T65, G77-T82, K88, Y94-Q97, R103-N112, D117E118, Y122D123, V134-C138, D145-S162, H167-K169, L175-A183, G195-D200, D204G205, F211-A216, K229-E236, Y242T243, Y259-P267, Q274-P276, E284G285, N294N 295, R312-Q319, I332-V340, L346-E348, Q367-E376, F387-K389, L392P393, Q402-D407, T413-C415, A419E420;
[0022] (d) a variant of the sequence shown in SEQ ID NO: 4, which has one or more amino acid modifications at the following positions: G154, E155, E157, L425, G428, I2-T8, K25-G27, P34-G38, G54-G57, A62-T64, G76-T81, K87, Y93-N96, R102-R111, D116E117, Y121D122, V133-C137, D144-S161, H166-K168, L174-G 182. G194-E199, D203G204, F210-A215, K228-E235, Y241-T244, Y258-N266, Q273-P275, D283G284, N293N294 , S311-E318, A331-T339, I345-D347, N367-Y373, F384-K386, L390-P391, Q339-N404, T410-C412, A416D417;
[0023] (e) a variant of the sequence shown in SEQ ID NO: 5, which has one or more amino acid modifications at the following positions: G154, E155, E157, L427, G430, I2-T8, K25-N27, P34-G38, G54-G57, A62-T64, G76-T81, K87, Y93-S96, K102-R111, D116E117, W121D122, I133-C137, D144-S161, H166-D168, L174- A182, G194-E199, D203G204, F210-A215, K228-E235, Y241T242, Y258-V266, Q273-P275, E283G284, T293N29 4. G311-E318, Y331-R338, I344-D346, N366-Y374, F385-K387, L391P392, Q400-D405, T411-C413, S417S418;
[0024] (f) A variant of the sequence shown in SEQ ID NO: 6, which has one or more amino acid modifications at the following positions: G153, E154, T156, L425, G428, M1-T7, K24-H26, P33-G37, G53-G56, A61-T63, G75-T80, K86, Y92-N95, K101-R110, D115E116, Y120D121, I132-C136, D143-S160, H165-K167, L173- A181, G193-D198, D202G203, F209-A214, K227-E234, F240T241, F257-V265, Q272-P274, D282G283, N292N29 3. K310-E317, Y330-R337, I343-S345, N365-P373, F384-K386, L390P391, Q399-D404, T410-C412, A416D417;
[0025] (g) a variant of the sequence shown in SEQ ID NO: 7, which has one or more amino acid modifications at the following positions: G153, E154, T156, L425, G428, M1-T7, K24-H26, P33-G37, G53-G56, A61-T63, G75-T80, K86, Y92-N95, K101-R110, D115E116, Y120D121, I132-C136, D143-S160, H165-K167, L173-A181, G193-D198, D202G203, F209-A214, K227-E234, F240T241, F257-V265, Q272-P274, D282G283, N292N293, K 310-E317, Y330-R337, I343-S345, N365-P373, F384-K386, L390P391, Q399-D404, T410-C412, A416D417;
[0026] (h) a variant of the sequence set forth in SEQ ID NO: 8, having one or more amino acid modifications at the following positions: G153, E154, T156, L425, G428, M1-T7, K24-H26, P33-G37, G53-G56, A61-T63, G75-T80, K86, Y92-N95, K101-R110, D115E116, Y120D121, I132-C136, D143-S160, H165-K167, L173- A181, G193-D198, D202G203, F209-A214, K227-E234, F240T241, F257-V265, Q272-P274, D282G283, N292N29 3. K310-E317, Y330-R337, I343-S345, N365-P373, F384-K386, L390P391, Q399-D404, T410-C412, A416D417;
[0027] (i) a variant of the sequence shown in SEQ ID NO: 9, which has one or more amino acid modifications at the following positions: G153, E154, T156, L423, G426, M1-T7, K24-H26, P33-G37, G53-G56, A61-T63, G75-T80, K86, Y92-N95, K101-R110, D115E116, C120D121, I132-C136, D143-S160, H165-K167, L173- A181, G193-D198, D202G203, Y209-D211, K224-E231, F237T238, L254-K262, Q269-P271, D279G280, N289N29 0. K307-E314, Y327-R335, I341-S343, F363-P371, F382-K384, L388P389, Q397-D402, T408-D410, A414D415;
[0028] (j) a variant of the sequence shown in SEQ ID NO: 10, which has one or more amino acid modifications at the following positions: G156, S157, E159, L429, G432, I2-K8, G25-Q29, P36-G40, G56-G59, A64-T66, G78-T83, K89, Y95-N98, K104-R113, D118E119, Y123D124, I135-C139, D146-S163, H168-D170, L176- A184, G196-D201, D205G206, F212-A217, K230-E237, F243T244, Y260-V268, Q275P276, E285G286, N295N296 , G313-E320, Y333-R341, I347-S349, N369-P377, F388-K390, L394-P395, Q403-D408, T414-C416, A420D421;
[0029] (k) a variant of the sequence shown in SEQ ID NO: 11, which has one or more amino acid modifications at the following positions: N156, S157, I159, L428, G431, L4-T10, K27-Q29, P36-G40, G56-G59, A64-T66, G78-T83, K89, Y95-A98, S104-R113, D118E119, Y123D124, V135-C139, D146-S163, N168-K170, L176-A184, G196-E201, N205G206, M212-S219, K232-E239, F245T246, Y262-N270, Q277-P279, E287G288, N297N298, A315-E322, I335-V340, I346- D348, N368-N376, F387-K389, L393P394, Q402-D407, T413-C415, A419D420;
[0030] (l) A variant of the sequence shown in SEQ ID NO: 12, which has one or more amino acid modifications at the following positions: G155, D155, S158, L429, G432, I3-T9, K26-T28, P35-G39, G55-G58, A63-T65, G77-T82, K88, Y94-N97, K103-R112, D117E118, W122D123, I134-C138, D145-S162, H167-D169, L175 -A183, G195E200, D204G205, F211-A216, K229-E236, F242T243, Y259-A267, Q274-P276, D284G285, N294N29 5. G312-E319, Y332-R340, I346-D348, N368-P376, F387-K389, L393P394, Q402-D407, T413-C415, S419N420;
[0031] (m) A variant of the sequence shown in SEQ ID NO: 13, which has one or more amino acid modifications at the following positions: G155, S156, V158, L428, G431, I2-N8, G25-N28, P35-G39, G55-G58, A63-T65, G77-T82, K88, Y94-S97, K103R112, D117E118, Y122D123, I134-C138, D145-S162, H167-D169, L175- A183, G195-D200, D204G205, F211-A216, K229-E236, F242T243, L259-T267, Q274-P276, E284G285, N294N29 5. S312-E319, Y332-L340, I346-D348, N368-P376, F387-K389, L393P394, Q402-D407, T413-C415, A419D420;
[0032] (n) A variant of the sequence shown in SEQ ID NO: 14, which has one or more amino acid modifications at the following positions: G150, S151, V153, L423, G426, M1-N3, G20-G23, P30-G34, G50-G54, A58-T60, G72-T77, K83, Y89-N92, K98-R107, D112E113, Y117D118, I129-C133, D140-S157, H162-D164, L170- A178, G190-E195, D199G200, F206-A211, K224-E231, F237T238, F254-V262, S269-P271, D279-G280, N289N2 90. G307-E314, Y327-R335, I341-D343, N363-P371, Y382-K384, L388P389, Q397-D402, T408C410, A414D415;
[0033] (o) A variant of the sequence shown in SEQ ID NO: 15, which has one or more amino acid modifications at the following positions: G153, D154, L156, A427, S430, M1-T7, K24-H26, P33-G37, G53-G57, A61-T63, G75-T80, K86, Y92-E95, K101-R110, D115E116, Y120D121, I 132-C136, D143-S160, H165-R167, L173-G181, G193-E198, D202G203, F209-P214, K227 -E234, Y240T241, Y257-V265, Q272-P274, D282G283, N292N293, K310-K317, V330-R338, L344-D346, E366-H375, F386-K388, L392P393, Q401-D406, T412-C414, A418D419;
[0034] (p) A variant of the sequence set forth in SEQ ID NO: 16 having one or more amino acid modifications at the following positions: G156, S157, G159, A430, G433, L3-K9, R26-G29, P36-G40, G56-G60, A64-T66, G78-T83, K89, Y95-Q98, R104-N113, D118E119, Y123G124, V135-C139, D146-S164, H169-S171, L177- T185, G197-E202, D206G207, F213-A218, K231-E238, F244T245, Y261-K269, Q276-P279, D286G287, N296N29 7. S314-R321, A334-V342, L348-A350, E369-P378, F389-K391, L395P396, Q404-N409, T415-C417, A421E422;
[0035] (q) a variant of the sequence set forth in SEQ ID NO: 17, having one or more amino acid modifications at the following positions: G153, D154, L156, A427, S430, M1-T7, K24-F26, P33-G37, G53-G57, A61-T63, G75-T80, K86, Y92-E95, K101-R110, D115E116, Y120D121, I132-C136, D143-S160, D165-R167, L173- G181, G193-E198, D202G203, F209-P214, K227-E234, Y240T246, Y257-V265, Q272-P274, D282G283, N292N29 3. K310-K317, V330-R338, L340-D346, E366-H375, F386-K388, L392P393, Q401-D406, T412-C414, A418D419;
[0036] (r) a variant of the sequence set forth in SEQ ID NO: 18, having one or more amino acid modifications at the following positions: N155, S156, G158, T429, G432, I3-T9, K26-K28, P35-G39, G55-G59, A63-T65, G77-T82, K88, Y94-N97, K103-R112, D117E118, Y122D123, I134-C138, D145-S163, D168-R170, L176- S184, G196-H201, D206G207, Y213-A219, R232-E239, Y245-T247, Y262-V270, Q277-P279, E287G288, H297N29 8. R315-E322, N335-R343, L349-D351, S371-H377, F388-K390, L394P395, Q403-D408, T414-C416, A420D421;
[0037] (s) a variant of the sequence set forth in SEQ ID NO: 19, having one or more amino acid modifications at the following positions: N167, S167, T170, L438, G441, L4-T10, K27-P40, P47-G51, G67-G70, A75-T77, G89-T94, K100, Y106-S109, S115-R124, D129E130, Y134D135, I146-C150, D157-S174, N179-K181, L187-A195, G207-E212, D216G217, M223-S230, K243-D250, F256T257, Y273-K281, Q288-P290, E298-G299, N308N309, F326-S333, V346-V351, I357 -D359, N379-N386, F397-K399, L403P404, Q412-D417, T423-C425, A429D430;
[0038] (t) a variant of the sequence shown in SEQ ID NO: 20, which has one or more amino acid modifications at the following positions: L426, G429, I2-T8, A25-K37, P44-G48, G64-G67, A72-T74, G86-T91, K97, Y103-K106, S112-R121, E126E127, Y131D132, I143-T147, D154-S167, D172-R174, L180-M188, G 200-E205, D209D210, D216-S218, K231-E238, Y244T245, Y261-V269, Q276-P278, E286G287, N296N297, K 314-Q321, I334-S339, I345-D347, S367-F373, Y384-R386, L390P391, Q399-D404, T410-C412, Y416A417;
[0039] (u) a variant of the sequence set forth in SEQ ID NO: 21, having one or more amino acid modifications at the following positions: G158, S159, G161, A432, G435, V5-N11, R28-E31, P38-G42, G58-G61, A66-T68, G80-T85, K91, Y97-Q100, R106-N115, D120E121, L125D126, I137-C141, D148-S166, H171-S173, L179- A187, G199-H204, D208G209, F215-A220, K233-E240, F246T247, Y263-N271, Q278-P280, D288-G289, N298-N29 9. I316-K323, I336-I344, L350-L352, E371-P380, F391-K393, L397P398, Q406-N411, T417-C419, A423-E424.
[0040] In a second aspect, the present invention provides a polynucleotide encoding the helicase mutant of the first aspect.
[0041] In a third aspect, the present invention provides a vector comprising the polynucleotide of the second aspect.
[0042] In a fourth aspect, the present invention provides a host cell comprising the vector of the third aspect.
[0043] Any host cell known in the art that is suitable for protein expression can be used as the host cell of the present invention, such as Escherichia coli cells.
[0044] In a fifth aspect, the present invention provides a kit comprising the helicase mutant of the first aspect.
[0045] In a sixth aspect, the present invention provides a method for improving the thermal stability of a helicase, the method comprising rigidifying the flexible region of the helicase.
[0046] In a seventh aspect, the present invention provides a method for producing the helicase mutant of the present invention, comprising transforming the host cell of the fourth aspect with the vector of the third aspect, and inducing the host cell to express the helicase mutant of the first aspect.
[0047] In an eighth aspect, the present invention provides a method for determining the presence, absence, or one or more characteristics of a target analyte, the method comprising:
[0048] (a) contacting the target analyte with a nanopore and the helicase mutant of the first aspect, such that the helicase mutant controls movement of the target analyte through the pore;
[0049] (b) applying an electric potential across the pore to mobilize the target analyte through the pore; and
[0050] (c) obtaining one or more characteristics of the target analyte when interacting with the pore to obtain the presence, absence or one or more characteristics of the target analyte.
[0051] In one embodiment, the target analyte is preferably a polysaccharide, a metal ion, an inorganic salt, a polymer, an amino acid, a peptide, a polypeptide, a protein, a nucleotide, an oligonucleotide, a polynucleotide, a dye, a drug, a diagnostic agent, an explosive or an environmental pollutant; or, the target analyte is selected from one or more of a polynucleotide, a polypeptide, a polysaccharide and a lipid, preferably a polynucleotide or a polypeptide, a polysaccharide and a lipid linked to a polynucleotide, more preferably a single-stranded polynucleotide, a double-stranded polynucleotide or a partially double-stranded polynucleotide. The method may involve determining the presence, absence or one or more characteristics of two or more target analytes of the same class, for example, two or more proteins, two or more nucleotides or two or more drugs. Alternatively, the method may involve determining the presence, absence or one or more characteristics of two or more target analytes of different classes, for example, one or more proteins, one or more nucleotides and one or more drugs. One or more characteristics include, but are not limited to, for example, the length, identity, specific sequence, secondary structure and modification (methylation, oxidation, damage, marker, tag or spacer modification, etc.) of the target analyte polynucleotide.
[0052] In one embodiment, the method of the eighth aspect can reduce sequencing speed, increase sequencing throughput and / or extend sequencing time.
[0053] In a preferred embodiment, the method of the eighth aspect is a nanopore sequencing method.
[0054] In a ninth aspect, the present invention provides use of the helicase mutant of the first aspect for analyzing the presence, absence or one or more characteristics of a target analyte.
[0055] In a preferred embodiment, the use of the ninth aspect is nanopore sequencing. BRIEF DESCRIPTION OF THE DRAWINGS
[0056] FIG1a shows the Coomassie Brilliant Blue staining results of the helicase mutant of the present invention and the corresponding helicase without rigidification of the flexible region (control, M2).
[0057] Figure 1b shows the thermal stability of the helicase mutants of the present invention and the corresponding helicase without rigidification of the flexible region (control, M2) under locked enzyme conditions. The Tm value of the protein was determined by protein thermal shift curve analysis. Statistics were performed using the one-way ANOVA statistical method. The figure shows a representative experiment, mean and SEM. * indicates P < 0.05, ** indicates P < 0.005, *** indicates P < 0.0005, and **** indicates P < 0.0001.
[0058] Figure 1c shows the helicase activity of the helicase mutants of the present invention and the corresponding helicase without rigidified flexible regions (control, M2) in the locked state in high-salt buffer and at room temperature. Statistics were analyzed using one-way ANOVA. The figure shows representative experiments, with means and SEM. * indicates P < 0.05, ** indicates P < 0.005, *** indicates P < 0.0005, and **** indicates P < 0.0001.
[0059] Figure 1d shows the results of incubation of the helicase mutants of the present invention and the corresponding helicase without rigidified flexible regions (control, M2) with the substrate ssDNA-M13 in a high-salt buffer (10 mM HEPES 7.0, 675 mM KCl, 25 mM MgCl2, 25 mM ATP) at 34°C for 2 h. HPLC analysis of the ADP content in the system reflects the ATPase activity of the helicase. The results of each mutant were normalized to those of M2.
[0060] Figure 1e shows TBE-native gel electrophoresis of a helicase mutant of the present invention and a corresponding helicase without rigidified flexible regions (control, M2) in the locked enzyme state after incubation in high-salt buffer (10 mM HEPES 7.0, 675 mM KCl) at 34°C for 0 hour (top) and 1 hour (bottom). The arrow indicates ssDNA-T44-HEX, and the parentheses indicate enzyme-bound substrates.
[0061] Figures 2a-d show the sequencing performance of the helicase mutants of the present invention and the corresponding helicase without rigidified flexible regions (control, M2). The sequencing was performed on a Qnome-3841 sequencer at 38°C for 24 hours using the same input. Figure 2a shows the relative read count, demonstrating a significant increase in read counts for the mutants of the present invention compared to the control. Figure 2b shows the relative throughput, Figure 2c shows the sequencing speed, and Figure 2d shows the distribution of sequencing speed over time. DETAILED DESCRIPTION
[0062] It will be understood that different applications of the disclosed products and methods can be adapted according to the specific needs of the art.It will also be understood that the terminology used herein is for the purpose of describing particular embodiments of the present invention only and is not intended to be limiting.
[0063] General Definition
[0064] Additionally, as used in the specification and claims, the singular forms "a," "an," and "the" include pluralities unless the context clearly dictates otherwise. For example, reference to "a helicase" includes two or more helicases.
[0065] As used herein, the terms "comprising," "including," and "having" mean that any listed elements must be included and that other elements may also be optionally included. "Consisting of" means that all unlisted elements are excluded. Embodiments defined by each of these terms are within the scope of the present invention.
[0066] As used herein, the term "about" in connection with all numerical values (including the lower and upper limits of numerical ranges) refers to any value with an acceptable variation of up to ±10% (e.g., ±0.5%, ±1%, ±1.5%, ±2%, ±2.5%, ±3%, ±3.5%, ±4%, ±4.5%, ±5%, ±5.5%, ±6%, ±6.5%, ±7%, ±7.5%, ±8%, ±8.5%, ±9%, ±9.5%).
[0067] As used herein, the term "high temperature" refers to temperatures above room temperature, for example above 20°C, above 25°C, above 30°C, above 40°C, above 50°C, above 60°C.
[0068] As used herein, the term "retaining helicase activity, ATPase activity and substrate binding ability" means that the helicase activity, ATPase activity and substrate binding ability are improved compared to the corresponding helicase without rigidification of the flexible region, for example, by at least 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 2 times or 3 times; or there is no significant change, that is, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the enzymatic activity of the corresponding helicase without rigidification of the flexible region.
[0069] As used herein, the term "increased sequencing throughput" refers to an increase in sequencing throughput of at least 1.5 times, at least 2 times, at least 5 times, at least 10 times, or at least 15 times compared to the corresponding helicase without rigidification of the flexible region.
[0070] As used herein, the term “naked enzyme” refers to a helicase that is not locked with a substrate, and a “locked enzyme” refers to a helicase that is locked with a substrate. In one embodiment, the locking enzyme forms a connection such as a covalent cross-link in the Pin-Tower region of the helicase, so that the helicase is in a conformational state that is more conducive to unwinding, while the substrate single-stranded DNA is enclosed in the arch formed by the protein and the Pin-Tower cross-linking, ensuring that the enzyme does not fall off from the ssDNA, thereby ensuring the continuity of sequencing. Methods for locking with substrates are known in the art, and can be found in, for example, WO2021253410A1.
[0071] As used herein, the term "mixed sequencing" refers to the mixing of libraries constructed with different enzymes using different sequences and then adding them to the same chip for sequencing, eliminating the impact of different chips on sequencing. The term "sequencing speed" refers to the length of the sequence to be tested divided by the time required for it to pass through the nanopore. The term "sequencing reads" refers to the number of sequences to be tested read by the sequencer. The term "sequencing throughput" refers to the number of bases of the sequence to be tested that pass through the nanopore within a certain period of time.
[0072] In the context of the present disclosure, the term "amino acid" is used in its broadest sense and is intended to include organic compounds containing amine (NH2) and carboxyl (COOH) functional groups and side chains (e.g., R groups) unique to each amino acid. In some embodiments, amino acids refer to naturally occurring Lα-amino acids or residues. Common single-letter and three-letter abbreviations for naturally occurring amino acids are used herein: A=Ala;C=Cys;D=Asp;E=Glu;F=Phe;G=Gly;H=His;I=Ile;K=Lys;L=Leu;M=Met;N=Asn;P=Pro;Q=Gln;R=Arg;S=Ser;T=Thr;V=Val;W=Trp;And Y=Tyr (Lehninger, AL, (1975) Biochemistry, 2nd ed., pp. 71-92, Worth Publishers, New York). The general term "amino acid" also includes D-amino acids, retro-inverso amino acids, and chemically modified amino acids (such as amino acid analogs), naturally occurring amino acids that are not typically incorporated into proteins (such as norleucine), and chemically synthesized compounds with properties known in the art to be characteristic of amino acids (such as β-amino acids). For example, analogs or mimetics of phenylalanine or proline are included in the definition of an amino acid, which allow the same conformational constraints on peptide compounds as natural Phe or Pro. Such analogs and mimetics are referred to herein as "functional equivalents" of the corresponding amino acids. Roberts and Vellaccio, The Peptides: Analysis, Synthesis, Biology, Gross and Meiehofer, eds., Vol. 5, p. 341, Academic Press, Inc., NY 1983, list other examples of amino acids, which are incorporated herein by reference.
[0073] The terms "protein," "polypeptide," and "peptide" are further used interchangeably herein to refer to polymers of amino acid residues, as well as variants and synthetic analogs of amino acid residues. Thus, these terms apply to amino acid polymers in which one or more amino acid residues is a synthetic non-naturally occurring amino acid, such as a chemical analog of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. Polypeptides may also undergo maturation or post-translational modification processes, which may include, but are not limited to, glycosylation, proteolytic cleavage, lipidation, signal peptide cleavage, propeptide cleavage, phosphorylation, and the like.
[0074] The term "wild-type" refers to a gene or gene product isolated from a naturally occurring source. A wild-type gene is the gene most commonly observed in a population and is therefore arbitrarily designed to be the "normal" or "wild-type" form of the gene. In contrast, the terms "mutant," "modified," or "variant" refer to a gene or gene product that exhibits sequence modifications (e.g., replacements, truncations, or insertions), post-translational modifications, and / or functional properties (e.g., altered properties) compared to a wild-type gene or gene product. "Amino acid modifications" herein include, for example, amino acid insertions, deletions, and / or substitutions.
[0075] Conservative substitutions replace amino acids with other amino acids of similar chemical structure, similar chemical properties, or similar side chain volume. The introduced amino acids can have similar polarity, hydrophilicity, hydrophobicity, basicity, acidity, neutrality, or charge as the amino acids they replace. Alternatively, conservative substitutions can introduce another aromatic or aliphatic amino acid in place of a pre-existing aromatic or aliphatic amino acid. Conservative amino acid changes are well known in the art, and it is well known that conservative substitutions of amino acids of similar properties generally do not affect the activity of the peptide sequence. Conservative substitutions are shown in Table 1.
[0076] Table 1 Conservative amino acid substitutions
[0077] Sequence homology or identity of amino acid or polynucleotide sequences can be determined by standard alignment algorithms and can be used with the default gap penalty established by the program being used. For example, homology, similarity or identity can be determined using BLAST or ClustalW from the National Center for Biotechnology Information (NCBI).
[0078] Rate-controlling enzymes and helicases
[0079] Rate-controlling enzyme can be any albumen that can combine polynucleotide and control it to move through hole.Rate-controlling enzyme often interacts with polynucleotide and modifies at least a property of polynucleotide.Described enzyme can be modified to form the short chain (for example, dinucleotide or trinucleotide) of each single nucleotide or nucleotide by cracking polynucleotide.Described enzyme can be modified by making polynucleotide orientation or moving it to specific position.Rate-controlling enzyme does not need to show enzymatic activity, as long as it can combine polynucleotide and control it to move through hole.For example, described enzyme can be modified to remove its enzymatic activity, or can be used under the condition that prevents it from being used as enzyme.
[0080] The rate-controlling enzyme is preferably a polymerase, an exonuclease, a helicase and a topoisomerase, for example, a gyrase. In one embodiment, the enzyme is preferably a helicase, which may be a member of, for example, helicase superfamily 1 (SF1) or superfamily 2 (SF2). The catalytic cores of SF1 and SF2 helicases have almost identical folds and extensive structural similarities, consisting of two similar protein domains, similar to the fold of the recombinant protein RecA, which can be further classified as Pif1-like helicase, Upf1-like helicase, UvrD / Rep helicase, Ski-like helicase, Rad3 / XPD helicase, NS3 / NPH-II helicase, DEAD helicase, DEAH / RHA helicase, RecG-like helicase, REcQ-like helicase, T1R-like helicase, Swi / Snf-like helicase and Rig-I-like helicase (see, e.g., Fairman-Williams ME et al., Curr Opin Struct Biol. 2010 Jun; 20(3): 313-24.).
[0081] Pif1-like helicases belong to the SF1B helicase (5'-3') family, including Dda from bacteriophage T4, RecD2 from bacteria, Pif1 from eukaryotes, and human DNA helicase B. This family of helicases typically consists of 1A, 2A, 1B, and 2B domains, unwinding and translocating single-stranded DNA substrates in the 5'-3' direction. The conserved motifs I-VI within the 1A and 2A domains form the ATP-binding pocket, while the 1B and 2B domains, together with the 1A and 2A domains, form the nucleic acid binding channel. The cycle of ATP binding, hydrolysis, release, and rebinding is coupled to the opening and closing of the nucleic acid binding channel and its translocation along the single-stranded DNA. Each ATP consumed causes the helicase to move one step toward the 3' end of the single-stranded DNA. This allows us to obtain current signal steps corresponding to the nucleotide sequence.
[0082] In a preferred embodiment of the present invention, the helicase is a Pif1-like helicase, or is selected from Hel308 helicase or a functional variant thereof, RecD helicase or a functional variant thereof, TraI helicase or a functional variant thereof, XPD helicase or a functional variant thereof, Dda helicase or a functional variant thereof, Edwardsiella phage PEi26 Pif1-like helicase or a functional variant thereof.
[0083] The flexible region rigidification strategy of the present invention can be used to transform any known helicase with sequencing activity. In this article, "corresponding helicase without flexible region rigidification" includes any wild-type SF1 or SF2 wild-type helicase that can control the movement of polynucleotides, and functional variants thereof. " Functional variant " of helicase of the present invention refers to having conservative or non-conservative amino acids or nucleotides inserted, deleted or replaced at one or more positions, but retains the helicase that controls the movement activity of polynucleotides. Helicases and functional variants thereof that can be used for sequencing are known in the art and can be, for example, found in CN107109380A, WO2021253410A1, US20150065354A1, EP2875128B1, etc. For example, it is known in the art that the sustainable sequencing ability of protein can be improved by modifying and transforming the protein, for example, by introducing specific amino acid residues (Cys or non-natural amino acids) on domains such as 1A and 2A, and locking them on nucleic acid linkers to carry out "lock enzyme" before sequencing. For methods of "locking enzymes", see WO2021253410A1. Other alternative ways of locking enzymes may exist now or in the future.
[0084] Rigidization of flexible areas
[0085] The loop region is a potentially flexible region in the protein structure and an important region for regulating enzyme catalytic activity, stability, and substrate specificity. It includes well-defined turns and more disordered random coils, which usually connect major secondary structures such as α-helices and β-sheets. The loop region is an important structural element in proteins and usually has higher sequence variability between homologs, thereby contributing to the diversification of functions within different evolutionary branches of the same superfamily. An increasing number of studies have shown that the loop region plays an important role in regulating enzyme catalysis, specificity, stability, and protein-protein interactions. A loop region that is too long may have a negative impact on protein folding. The flexible region can be rigidified by truncating the amino acid sequence of the loop region.
[0086] Alternatively, the flexible region can be rigidified based on the amino acid preference for the most common secondary structure, the β-turn, within the loop region. A β-turn consists of four amino acids (i, i+1, i+2, i+3) and is classified into classes I-IX based on the dihedral angles between amino acids i+1 and i+2. Studies have shown that among the 426 protein β-turns analyzed, Pro, Met, and Trp are more frequently present, while Val, Gly, Ala, and Gln are less frequently present. At the same time, the frequency of certain fixed amino acid residues appearing at different positions of the structure also varies. For example, Pro prefers to be at the i+1 position in type I and type II, and Gly prefers to be at the i+3 position in type I and the i+2 position in type II. In type II β-turn, the preference statistics of amino acid residues at different positions are as follows: i: Cys, Pro; i+1: Ala, Gln, Lys, Pro; i+2: Gly, Asn; i+3: Cys, Asp, Lys, Gln, Ser, Tyr.
[0087] The development of structural biology and bioinformatics has made it possible to more accurately locate the flexible sites of proteins through analysis of some structural parameters (such as B-factor, RMSF value, Gibbs free energy, etc.) or homologous sequence comparison.
[0088] The B-factor, also known as the temperature factor, reflects the "ambiguity" of atomic electron density in a crystal. The greater the "ambiguity," the more unstable the conformation at the corresponding site. Because the B-factor is derived from the crystal structure, it reflects the static stability of the protein. Various algorithms, such as canonical mode analysis, elastic network models, Gaussian network models, flexibility and rigidity index methods, and multiscale weighted color map models, have been developed to accurately predict protein B-factors. Protein B-factors can also be obtained from the B-Factor Database (BDB) (http: / / www.cmbi.ru.nl / bdb / ) or using computational tools such as B-FITTER and YASARA. B-factor spectra have been shown to be effective in analyzing flexible sites in proteins. However, the use of B-factors has some limitations. Accurate prediction of protein B-factors requires high-quality protein structures. B-factor values can vary significantly between proteins depending on structural refinement and crystal quality.
[0089] RMSF / RMSD is obtained through molecular dynamics simulations and reflects the dynamic stability of a protein. Furthermore, a stable protein generally exhibits the lowest Gibbs free energy. Therefore, Gibbs free energy predictions for protein conformations using software such as Rosetta / Fold X can be used to determine the impact of different sites on protein conformational stability. Multiple sequence alignments of homologous proteins can identify sites that differ from homologous proteins from thermostable species, providing candidate sites and mutation targets for improving thermal stability.
[0090] However, the strategy of rigidifying flexible regions currently has a low success rate. First, there is still limited understanding of how to identify the best candidate mutation sites. Second, there is a restrictive relationship between the catalytic activity and stability of an enzyme: the rigidity of the structure determines thermal stability, while the flexibility determines the catalytic activity. Mutants with higher thermal stability tend to have lower catalytic activity. To realize the utilization value of enzymes under high temperature conditions, it is obviously undesirable to improve thermal stability at the expense of enzyme catalytic activity.
[0091] The inventors unexpectedly discovered that the helicase mutants of the present invention retain the ability to control the movement of polynucleotides through the nanopore after the flexible region is rigidified, and have improved sequencing performance, for example, they can reduce the sequencing speed, increase the number of sequencing reads within the same sequencing time, extend the sequencing time, increase the sequencing throughput, or improve the sequencing accuracy.
[0092] In addition, the helicase mutants of the present invention can have improved thermal stability while retaining helicase activity, ATPase activity, and substrate binding ability. The helicase activity of the mutants can be measured using a variety of methods, such as the fluorescence analysis method described in the Examples. The ATPase activity of the mutants can be measured using radiolabeling or by quantitative phosphate consumption as described in the Examples. Methods for determining the substrate binding ability of the mutants include, but are not limited to, fluorescence anisotropy, tryptophan fluorescence, and gel mobility shift assay (EMSA).
[0093] Polynucleotides, vectors, host cells
[0094] The present invention provides a polynucleotide encoding the helicase mutant of the present invention, a vector comprising the polynucleotide, and a host cell comprising the vector.
[0095] Any protein described herein can be expressed using methods known in the art. Polynucleotide sequences can be isolated and replicated using standard methods in the art. DNA encoding helicases can be isolated from organisms that produce helicases, such as T4 phage. PCR amplification of the gene encoding sequence of interest can be used with specific primers. The amplified sequence can then be inserted into a recombinant replication vector, such as a cloning vector. The vector can be used to replicate the polynucleotide in a compatible host cell. Therefore, polynucleotide sequences can be prepared by introducing the polynucleotide encoding the sequence of interest into a replicable vector, including introducing the vector into a compatible host cell, and growing the host cell under conditions that induce vector replication. The vector can be recovered from the host cell.
[0096] The polynucleotide sequence can be cloned into an appropriate expression vector. In the expression vector, the polynucleotide sequence is usually operably linked to a control sequence that can provide for the expression of the coding sequence by the host cell.
[0097] The term "operably linked" refers to a juxtaposition wherein the described components are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated under conditions compatible with the control sequences in such a manner as to achieve expression of the coding sequence. Multiple copies of the same or different polynucleotides may be introduced into a vector.
[0098] The vector can be, for example, a plasmid, virus or phage vector having an origin of replication, optionally a promoter for expressing the polynucleotide sequence, and optionally a regulatory factor for the promoter. The vector can contain one or more selectable marker genes, such as an ampicillin resistance gene. Promoters and other expression control signals compatible with the host cell for which the vector is designed can be selected. Typically, T7, trc, lac, ara or k promoters are used.
[0099] The host cell typically expresses the enzyme at high levels. A host cell compatible with the vector used to transform the host cell is selected for polynucleotide sequence transformation. The host cell is typically bacterial and preferably Escherichia coli. Any cell with a lambda DE3 lysogen, such as Rosetta2(DE3)pLys, C41(DE3), BL21(DE3), JM109(DE3), B834(DE3), TUNER, Origami, and Origami B, can express vectors containing a T7 promoter.
[0100] Reagent test kit
[0101] The present invention also provides a kit for characterizing a target analyte (e.g., a target polynucleotide), comprising the helicase mutant of the present invention. The kit may also comprise components for forming a nanopore or membrane, such as a phospholipid required for forming an amphiphilic layer (e.g., a lipid bilayer).
[0102] The test kit may additionally comprise one or more other reagents or instruments that enable any of the embodiments mentioned above to be performed. Such reagents or instruments include one or more of the following: a suitable buffer (aqueous solution), a device for obtaining a sample from an individual (such as a container or instrument comprising a needle), a device for amplifying and / or expressing a polynucleotide, or a voltage or patch clamp device. The reagents may be present in the test kit in a dry form so that the fluid sample resuspends the reagent. The test kit may also optionally include instructions for enabling the use of the test kit with the method of the present invention or details on which organisms the method can be used with.
[0103] Device
[0104] The present invention also provides an apparatus for characterizing a target analyte (e.g., a target polynucleotide) comprising a helicase mutant of the present invention. The apparatus preferably also includes instructions for implementing the methods of the embodiments. The apparatus can be any conventional apparatus for analyte analysis, e.g., an array or chip. The apparatus can also include any features present in the kit described herein.
[0105] In one embodiment, the apparatus comprises: a sensor device capable of supporting a plurality of pores and operable to characterize a polynucleotide using the pores and a helicase; and at least one port for delivering a material for characterization. In one embodiment, the apparatus comprises: a sensor device capable of supporting a plurality of pores and operable to characterize a polynucleotide using the pores and a helicase; and at least one reservoir for storing a material for characterization; a fluidics system configured to controllably provide the material from the at least one reservoir to the sensor device; and one or more containers for receiving corresponding samples, the fluidics system being configured to selectively provide the sample from the one or more containers to the sensor device.
[0106] The device may be any one of those described in WO2009 / 077734, WO2010 / 122293, WO2011 / 067559 or WO00 / 28312. Specifically, the device may be a QNome-9604 or QNome-3841 gene sequencer from Qi Tan Technology.
[0107] hole
[0108] The pores are structures that allow hydrated ions to flow from one side of the membrane to the other, driven by an applied electric potential.
[0109] Further preferably, the pore is a nanopore, and the nanopore is a transmembrane pore. The transmembrane pore provides a channel for the migration of the target polynucleotide. Further preferably, the pore is selected from a biological pore, a solid-state pore, or a biological-solid-state hybrid pore.
[0110] In some embodiments, the pore includes but is not limited to pores derived from Mycobacterium smegmatis porin A (MspA), Mycobacterium smegmatis porin B, Mycobacterium smegmatis porin C, Mycobacterium smegmatis porin D, hemolysin, lysin, interleukin, outer membrane porin F, outer membrane porin G, outer membrane phospholipase A, CSGG, WZA or Neisseria autotransporter lipoprotein; graphene nanopore, MoS2 nanopore, BN nanopore or PA63 nanopore, optionally, the pore is selected from MspA nanopore or CSGG nanopore.
[0111] Methods for determining the presence, absence, or one or more characteristics of a target analyte
[0112] The present invention also provides a method for determining the presence, absence, or one or more characteristics of a target analyte, the method comprising using a helicase mutant of the present invention. The one or more characteristics are preferably selected from (i) the length of the polynucleotide, (ii) the identity of the polynucleotide, (iii) the sequence of the polynucleotide, (iv) the secondary structure of the polynucleotide, and (v) whether the polynucleotide is modified. In one embodiment, any combination of (i) to (v) can be measured.
[0113] For (i), the length of the polynucleotide may be measured, for example, by determining the number of interactions between the polynucleotide and the pore or the duration of interactions between the polynucleotide and the pore.
[0114] Regarding (ii), the identity of a polynucleotide can be measured in a variety of ways. The identity of a polynucleotide can be measured in conjunction with or without measuring the polynucleotide sequence. The former is relatively simple; the polynucleotide is sequenced and identified. The latter can be accomplished in several different ways. For example, the presence of a specific motif in a polynucleotide can be measured (without measuring the rest of the polynucleotide sequence). Alternatively, the measurement of a specific electrical and / or optical signal in the described methods can identify the polynucleotide as originating from a specific source.
[0115] For (iii), the sequence of the polynucleotide can be determined as previously described. Suitable sequencing methods, in particular sequencing methods using electrical measurement methods, are described in Stoddart D et al., Proc Natl Acad Sci, 12; 106(19): 7702-7, Lieberman KR et al., J Am Chem SoC. 2010; 132(50): 17961-72 and WO2000 / 28312.
[0116] Regarding (iv), secondary structure can be measured using a variety of methods. For example, if the method involves electrical measurement, changes in residence time or changes in the current flowing through the pore can be used to measure the secondary structure. This allows for differentiation between regions of single-stranded and double-stranded polynucleotides.
[0117] For (v), the presence or absence of any modifications can be measured. The method preferably comprises determining whether the polynucleotide is modified by methylation, oxidation, damage, modification with one or more proteins, or modification with one or more markers, tags, or modification without bases or lacking nucleobases and sugars. Specific modifications will result in specific interactions with the pore, which can be measured using the following methods. For example, methylcytosine can be distinguished from cytosine based on the current flowing through the pore during its interaction with each nucleotide.
[0118] In one embodiment, the method includes electrical measurement and optical measurement. Electrical measurement includes voltage measurement, capacitance measurement, current measurement, impedance measurement, tunneling measurement (Ivanov AP et al., Nano Lett. 2011 Jan 12; 11 (I): 279-85) and FET measurement (International Application WO 2005 / 124888). Optical measurement can be combined with electrical measurement (Soni GV et al., Rev Sci Instrum. 2010 Jan; 81 (1) 014301). The measurement can be a transmembrane current measurement, such as a measurement of an ion current flowing through the pore. In one embodiment, the electrical measurement or optical measurement can be a conventional electrical or optical measurement. Electrical measurements can be performed using standard single-channel recording equipment as described in Stoddart D et al., Proc Natl Acad Sci, 12; 106(19)7702-7, Lieberman KR et al, J Am Chem SoC. 2010; 132(50)17961-72 and international application WO 2000 / 28312. Alternatively, electrical measurements can be performed using a multi-channel system, such as described in international application WO 2009 / 077734 and international application WO 2011 / 067559.
[0119] The method is preferably performed using an applied potential across the membrane. The applied potential may be a voltage potential. Alternatively, the applied potential may be a chemical potential. One example is the use of a salt gradient across the membrane, such as across a layer of amphiphilic molecules. Salt gradients are disclosed in Holden et al., J Am Chem SOC. 2007 Jul 11;129(27):8650-5. In some cases, the current flowing through the mutant protein monomer / protein pore as the polynucleotide moves relative to the mutant protein monomer / protein pore is used to estimate or determine the sequence of the polynucleotide. This is known as strand sequencing.
[0120] The method may include measuring the current flowing through the pore as the polynucleotide moves relative to the pore. Thus, the apparatus used in the method may also include circuitry capable of applying an electric potential and measuring the electrical signal passing through the membrane and the pore. The method may be performed using a patch clamp or a voltage clamp.
[0121] The method can include measuring the current flowing through the hole when the polynucleotide moves relative to the hole. Suitable conditions for measuring the ion flow through the transmembrane protein pore are known in the art and disclosed in the examples. The method is usually performed by applying a voltage to the membrane and the hole. The voltage used is usually from +5V to -5V, for example from +4V to -4V, from +3V to -3V or from +2V to -2V. The voltage used is usually from -600mV to +600V or -400mV to +400mV. The voltage used is preferably within a range having a lower limit selected from -400mV, -300mV, -200mV, -150mV, -100mV, -50mV, -20mV and 0mV and an upper limit independently selected from +10mV, +20mV, +50mV, +100mV, +150mV, +200mV, +300nV and +400mV. The voltage used is more preferably within a range of 100mV to 240mV and most preferably within a range of 120mV to 220mV. By using an increased applied potential, the recognition of different nucleotides by the pore can be increased.
[0122] The method is generally carried out in the presence of any charge carrier, such as a metal salt such as an alkali metal salt, a halide salt such as a chloride salt, such as an alkali metal chloride salt. The charge carrier can include an ionic liquid or an organic salt, such as tetramethylammonium chloride, trimethylphenylammonium chloride, phenyltrimethylammonium chloride or 1-ethyl-3-methylimidazolium chloride. In the exemplary device described above, the salt is present in an aqueous solution in the chamber. Potassium chloride (KCl) is generally used, Sodium chloride (NaCl), cesium chloride (CsCl) or a mixture of potassium ferrocyanide and potassium ferricyanide. A mixture of KCl, NaCl and potassium ferrocyanide and potassium ferricyanide is preferred. The charge carrier can be asymmetric on the membrane. For example, the type and / or concentration of the charge carrier can be different on each side of the membrane.
[0123] The concentration of the salt may be saturating. The concentration of the salt may be 3 M or less, and is typically 0.1 to 2.5 M, 0.3 to 1.9 M, 0.5 to 1.8 M, 0.7 to 1.7 M, 0.9 to 1.6 M or 1 M to 1.4 M. The concentration of the salt is preferably 150 mM to 1 M. The method is preferably performed using a salt concentration of at least 0.3 M, such as at least 0.4 M, at least 0.5 M, at least 0.6 M, at least 0.8 M, at least 1.0 M, at least 1.5 M, at least 2.0 M, at least 2.5 M or at least 3.0 M. High salt concentrations provide a high signal-to-noise ratio and allow the presence of the nucleotide to be identified in the context of normal current fluctuations to be indicated by current.
[0124] The method is typically performed in the presence of a buffer. In the exemplary apparatus described above, the buffer is present in an aqueous solution in the chamber. Any buffer may be used in the method of the present invention. Typically, the buffer is a phosphate buffer. Other suitable buffers are HEPES or Tris-HCl buffer. The method is typically performed at a pH of 4.0 to 12.0, 4.5 to 10.0, 5.0 to 9.0, 5.5 to 8.8, 6.0 to 8.7, 7.0 to 8.8, or 7.5 to 8.5. The pH used is preferably about 7.5.
[0125] The method can be carried out at a temperature of 0°C to 100°C, 15°C to 95°C, 16°C to 90°C, 17°C to 85°C, 18°C to 80°C, 19°C to 70°C, or 20°C to 60°C. The method is typically carried out at room temperature. The method is optionally carried out at a temperature that supports the function of the enzyme and the system in which it is located, such as about 37°C or about 38°C.
[0126] In a preferred embodiment, the method comprises:
[0127] (a) contacting the target analyte with a nanopore and a helicase mutant of the invention, such that the helicase mutant controls movement of the target analyte through the pore;
[0128] (b) applying an electric potential across the pore to mobilize the target analyte through the pore; and
[0129] (c) obtaining one or more characteristics of the target analyte when interacting with the pore to obtain the presence, absence or one or more characteristics of the target analyte.
[0130] The above-mentioned prior art is incorporated herein by reference in its entirety.
[0131] The following examples are provided to illustrate the present invention but are not intended to limit the present invention.
[0132] Example
[0133] Example 1. Expression and purification of helicase mutants and corresponding helicases without rigidification of flexible regions in Escherichia coli
[0134] In the embodiment, the corresponding helicase M2 without rigidification of the flexible region is a Pif1-like helicase shown in SEQ ID NO: 1, and the Pif1-like helicase is derived from Edwardsiella phage PEi26 Pif1-like helicase (Uniprot ID: A0A0B6VP37), and further includes M1G / D99C / V155I / F246Y / E286K / S293N / C308T / A366C / C419D site mutations based on the sequence shown in SEQ ID NO: 6 disclosed in WO2021253410A1. The two sites with higher B factors in its amino acid sequence are shown in Table 2.
[0135] Table 2 Two amino acid sites with higher B factors in M2
[0136] By site-directed mutagenesis of the Loop region and higher amino acid positions of factor B, plasmids encoding the helicase mutants shown in Table 3 were obtained.
[0137] Table 3 Helicase mutants with rigid flexible regions
[0138] The synthesized mutant gene plasmid was heat-shock transformed into Escherichia coli competent cells BL21(DE3)Plys to obtain a recombinant strain. Monoclonal colonies on the plates were selected for strain preservation. The revived seeds were cultured for seed expansion. After IPTG-induced protein expression for 20 hours, the cells were collected. The resulting cells were homogenized, and the supernatant was collected for Western blotting to detect target protein expression. The expressed mutant was purified and the recombinant enzyme was obtained (Figure 1a).
[0139] Example 2. Analysis of helicase activity of helicase mutants and corresponding helicases without rigidification of flexible regions
[0140] The helicase mutant and the corresponding helicase without rigidified flexible region were reacted with fluorescent substrates, which had a 5' end ssDNA protrusion, a 50 base hybridized dsDNA part, and two 3' ends with fluorescent groups and quenching groups respectively. As the helicase moves from the 5' end to the 3' end, the fluorescent groups are released when the double strands are unwound, thereby increasing the detected fluorescent signal. The amplitude of the increase in the fluorescent signal reflects the level of helicase activity. After incubation of the fluorescent substrate with the enzyme and cross-linking, the ATP / Mg 2+ The changes in fluorescence signals were recorded simultaneously to determine the relative helicase activity of the mutant relative to the M2 control. It was found that the helicase activity of the mutant was similar to that of the M2 control, ranging from 0.5-1.1 times that of the control (Figure 1c).
[0141] Example 3. ATPase activity analysis of helicase mutants and corresponding helicases without rigidification of flexible regions
[0142] The helicase was cross-linked to a single-stranded DNA substrate, and the complex was incubated in a sequencing environment for 2 hours. The amount of ATP consumed and ADP produced by the rate-controlling enzyme was measured by HPLC, reflecting the relative ATPase activity of the mutants. As shown in Figure 1d, the ATPase activity of most helicase mutants remained largely unchanged at 34°C, ranging from 0.46-1.00 times that of the control. The combined S32 and S33 mutations exhibited a high Tm value (see Figure 1b). Although the ATPase activity was reduced by more than half compared to M2, resulting in a slower sequencing speed, the mutants achieved higher read counts and throughput compared to M2 (see Figures 2a-2c).
[0143] Example 4. Analysis of ssDNA substrate binding ability of helicase mutants and corresponding helicases without rigidification of flexible regions
[0144] The helicase mutants and M2 controls were cross-linked with fluorescently labeled T44, respectively. After incubation at 34°C for 0 hour or 1 hour under high salt conditions, the affinity of single-stranded DNA to the rate-controlling enzyme and its mutants was detected by TBE non-denaturing gel electrophoresis. It was found that at 0h, the migration rate of the fluorescent substrate added to the enzyme slowed down relative to the T44 substrate, and the difference in migration slowdown between different mutants was not much (as shown in the upper figure of Figure 1e). After 1 hour of high salt heating, the mutants of the present invention improved the affinity of the substrate to the enzyme to varying degrees (as shown in the lower figure of Figure 1e). Compared with M2, except for S03 / S04 / S21, whose affinity to the substrate was not significantly improved, the affinity of all other mutants to the substrate was significantly improved.
[0145] Example 5. Thermal stability analysis of helicase mutants and corresponding helicases without rigidification of flexible regions
[0146] The basic principle of enzyme thermostability assays is that proteins unfold during continuous heating, exposing hydrophobic core regions. Binding to these hydrophobic regions results in fluorescence. As more protein unfolds, fluorescence gradually increases, reaching a peak at a certain point. Then, as the unfolded proteins aggregate, fluorescence gradually decreases, forming an inverted U-curve. The assay involves mixing the protein, buffer, and protein fluorescent dye and running a melting curve experiment on a Bio-Rad CFX96 real-time quantitative PCR instrument or other suitable qPCR instrument. As the protein unfolds upon heating, the fluorescent dye binds to the exposed hydrophobic regions and fluoresces. The rate of change is determined by plotting a negative-one regression plot of relative fluorescence versus temperature, resulting in a visible peak representing the melting temperature (Tm) of the protein in the corresponding buffer. We crosslinked the helicase to a substrate and examined the thermostability of the helicase after forming a complex with the substrate (Figure 1b). We found that the helicase mutants of the present invention had an increased Tm relative to the control M2.
[0147] Example 6 Application of Helicase Mutants and Corresponding Helicases Without Rigidization of Flexible Regions in Nanopore Sequencing
[0148] Libraries of the helicase mutants and the corresponding helicases without rigid flexible regions were constructed separately and mixed for 24 hours at 38°C using the same input amount on a Qnome-3841 sequencer. Analysis of sequencing speed, relative read counts, and relative throughput was performed according to the instructions in the Qnome-3841 sequencer manual. The results showed that the sequencing speed of the flexible region rigid mutants was slightly reduced at high temperatures compared to the corresponding helicases without rigid flexible regions (Figure 2c). However, the number of sequencing reads within the same sequencing time was significantly increased (Figure 2a), and the relative throughput was also significantly increased (Figure 2b). The temporal distribution of sequencing reads indicated that the flexible region rigid mutants prolonged sequencing time (Figure 2d).
[0149] Example 7: Other directions of rigidification of the flexible zone
[0150] First, for the G158, S159, G161, A432 and G435 sites mutated in Example 1, other mutation directions can also be selected. For example, for the G158 site, the optional amino acid modification includes deletion or replacement with P / N / Q; for the S159 site, the optional amino acid modification includes deletion or replacement with D / E / A / T / Y / N / Q; for the G161 site, the optional amino acid modification includes deletion or replacement with E / Q / T / I / V / L / S / M / N / Y; for the A432 site, in addition to mutation to L, mutation to other amino acids with larger side chains or stronger rigidity, the optional amino acid modification includes replacement with L / V / I / T / S / M / Y / N / Q / P / W / F; for the G435 site, the optional amino acid modification includes replacement with A / S / L / V / I / T / M / Y / N / Q / P / W / F.
[0151] Similarly, the corresponding amino acid sites of G158, S159, G161, A432 and G435 in other helicases (see Table 3) can also be rigidified in the flexible regions to improve sequencing performance. The optional amino acid modifications for flexible region mutations are summarized in the last row of Table 4.
[0152] Table 4 Corresponding amino acid positions of G158, S159, G161, A432 and G435 in other helicases
[0153] In addition, the regions that can be rigidified in the flexible region are not limited to the corresponding amino acid sites of G158, S159, G161, A432 and G435, but can also be amino acid sequences that show a loop secondary structure in the helicase structure. The corresponding positions in homologous proteins are shown in Table 5 below.
[0154] Table 5 Loop region in helicase
Claims
1. A helicase mutant whose flexible region is rigidified and retains the ability to control the movement of a polynucleotide through a nanopore.
2. The helicase mutant according to claim 1, wherein the helicase mutant has improved sequencing performance compared to the corresponding helicase without rigidification of the flexible region, such as reduced sequencing speed, increased number of sequencing reads within the same sequencing time (or increased pore frequency), increased sequencing throughput and / or extended sequencing time.
3. The helicase mutant according to claim 1 or 2, wherein the flexible region is rigidified by one or more amino acid modifications at the Loop region and / or amino acid residues with higher B factors.
4. The helicase mutant according to any one of claims 1 to 3, wherein the corresponding helicase that has not been rigidified by the flexible region is a helicase of helicase superfamily 1 or superfamily 2 or a functional variant thereof, preferably a Pif1-like helicase, Upf1-like helicase, UvrD / Rep helicase, Ski-like helicase, Rad3 / XPD helicase, NS3 / NPH-II helicase, DEAD helicase, DEAH / RHA helicase, RecG-like helicase, REcQ-like helicase, T1R-like helicase, Swi / Snf-like helicase or Rig-I-like helicase or a functional variant thereof, more preferably a Pif1-like helicase or a functional variant thereof.
5. The helicase mutant according to any one of claims 1 to 4, wherein the corresponding helicase that has not been rigidified by the flexible region comprises the amino acid sequence shown in SEQ ID NO: 1 or comprises an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% identical to the amino acid sequence shown in SEQ ID NO: 1, and the helicase mutant has one or more amino acid modifications at the following sites corresponding to SEQ ID NO: 1: G158, S159, G161, A432 and G435, preferably the helicase mutant has one or more of the following amino acid modifications: ΔG158 / ΔS159, ΔG161, A432L, G435A.
6. A polynucleotide encoding the helicase mutant according to any one of the preceding claims. A vector comprising the polynucleotide according to claim 6. A host cell comprising the vector according to claim 7.
9. A method for preparing a helicase mutant according to any one of claims 1 to 5, comprising expressing a nucleic acid according to claim 6, transfecting a cell with an expression vector according to claim 7, or culturing a host cell according to claim 8.
10. A construct comprising the helicase mutant described in any one of claims 1 to 5 or the helicase mutant prepared by the method of claim 9, and a loading portion bound to the helicase mutant. Optionally, the construct further comprises a target analyte, which is located in a preset moving direction of the helicase mutant.
11. A product comprising the helicase mutant according to any one of claims 1 to 5, the nucleic acid according to claim 6, the vector according to claim 7, the host cell according to claim 8, the helicase mutant prepared by the method according to claim 9 or the construct according to claim 10, and a pore, wherein the product is used to determine the presence, absence or one or more characteristics of a target analyte; Optionally, the product is selected from a kit, a device or a sensor.
12. A method for determining the presence, absence or one or more characteristics of a target analyte, the method include: (a) contacting the target analyte with a nanopore and a helicase mutant according to any one of claims 1 to 5 or a helicase mutant prepared by the method of claim 9, such that the helicase mutant controls the movement of the target analyte through the pore; (b) applying an electric potential across the pore to cause the target analyte to migrate through the pore; as well as (c) obtaining one or more characteristics of the target analyte when interacting with the pore to obtain the presence, absence or one or more characteristics of the target analyte.
13. The product according to claim 11 or the method according to claim 12, wherein the target analyte is selected from one or more of polynucleotides, polypeptides, polysaccharides and lipids, preferably polynucleotides or polypeptides, polysaccharides and lipids linked to polynucleotides, more preferably single-stranded polynucleotides, double-stranded polynucleotides or partially double-stranded polynucleotides; wherein the one or more characteristics are selected from the group consisting of length, identity, specific sequence, secondary structure, and modification (methylation, oxidation, damage, marker, tag, or spacer modification) of the target analyte; The pore is selected from a biological pore, a solid-state pore or a hybrid biological and solid-state pore.
14. The helicase mutant according to any one of claims 1 to 5, the nucleic acid according to claim 6, the vector according to claim 7, the host cell according to claim 8, the helicase mutant prepared by the method according to claim 9, the construct according to claim 10, the product according to claim 11, or the use of the method according to any one of claims 12-13 in preparing a product for characterizing a target analyte or in characterizing a target analyte.
Citation Information
Patent Citations
Enzyme construct
US20150218629A1
Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
US20170058338A1
Modified nanopores, compositions comprising the same, and uses thereof
US20200010511A1
Pif1-like helicase and application thereof
WO2021253410A1
